Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington, involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer. It was founded in 1994. It operated a laboratory and production facility in Hamilton, Montana.

Founded1994 in Seattle, Washington
DefunctMarch 31, 2006 (2006-03-31)
Successoracquired by GlaxoSmithKline
Number of locations
ParentGlaxoSmithKline (United States) Edit this on Wikidata

The name Corixa comes from the true bug (Insecta: Hemiptera: Heteroptera) genus Corixa (family Corixidae, Water boatman), described by Geoffroy, in 1762.[citation needed]

On 12 July 2005[citation needed], the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa.[1] GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.

On 31 March 2006, Corixa's doors closed after over 11 years in business.[citation needed]

External links edit

  • "Corixa Corporation - powering the immune system". Archived from the original on 2006-03-01.

References edit

  1. ^ "Glaxo to acquire Corixa for $300 million". Market Watch. April 29, 2005.

47°36′58″N 122°20′03″W / 47.615976°N 122.334242°W / 47.615976; -122.334242